Requiring coverage of treatment for certain pediatric autoimmune neuropsychiatric disorders in certain circumstances

SB 884 requires health insurance plans (including Medicaid) to cover intravenous immunoglobulin (IVIG) therapy for children diagnosed with specific conditions, including pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute onset neuropsychiatric syndrome (PANS). The bill applies to all health insurance plans issued or renewed after January 1, 2027, directly affecting pediatric patients with these conditions and their insurers. Key provisions mandate that physicians must obtain prior authorization by demonstrating all other treatment options have been exhausted before IVIG coverage is approved. This law aims to standardize coverage for these complex neurological conditions while adding a clinical review step to ensure appropriate use of the treatment.